Among the genes identified in genome-wide RNAi screens for novel apoptotic regulators (see abstract by McCloskey and Rothman) is
tfg-1 , the C. elegans homologue of human TFG (TRK-fused gene). TFG was originally identified on the basis of its rearrangement in chromosomal translocations present in papillary thyroid carcinomas and anaplastic large cell lymphomas. These rearrangements create in-frame fusions of TFG coding sequences with the receptor tyrosine kinase, ALK (anaplastic lymphoma kinase). TFG transcription is also up-regulated in response to activation of the TNF receptor family member TALL-1, which promotes proliferation of B lymphocytes and autoimmunity. We have found that that loss of
tfg-1 activity results in a slight increase in CED-3-independent cell death. While this effect is mild, we also observed that RNAi of
tfg-1 results in small, uncoordinated, and sterile phenotypes, all three of which are suppressed by a
ced-4 , but not a
ced-3 mutation. Thus, the Sma Unc Ste phenotypes might be the result of CED-4-dependent apoptosis, as is seen in
icd-1 and
icd-2 mutants (see abstract by Bloss and Rothman). While the function of human TFG in tumorigenesis is unknown, these results suggest that
tfg-1 might act to suppress apoptosis, leading to the hypothesis that TFG might contribute to tumor formation by inappropriately repressing apoptosis, in analogy to the action of the anti-apoptotic factor, Bcl-2, in promoting lymphomas. Such an anti-apoptotic function could also explain a role for TFG in autoimmunity. Current studies are directed at illuminating the action of
tfg-1 in repression of apoptosis.